A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
A Single-arm, Open-label, Multicenter Phase II Clinical Study of AK105 in Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Second and Subsequent Lines of Chemotherapy
Sponsor: Akeso
This PHASE2 trial investigates Nasopharyngeal Carcinoma and is currently completed. Akeso leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2022 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 3 earlier versions
-
Oct 2021 — May 2022 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akeso
- Akeso Tiancheng, Inc
For direct contact, visit the study record on ClinicalTrials.gov .